A Phase I Study of Hetrombopag Olamine in Healthy Adult Volunteers

Study Overview
=================
Brief Summary
-----------------
Hetrombopag Olamine made by Jiangsu Hengrui Medicine co Ltd. has shown an effect of increasing platelet count in animal and human. This study is designed in dose escalation fashion to evaluate safety, pharmacokinetics and efficacy of Hetrombopag Olamine.

Detailed Description
-----------------
To evaluate safety and tolerability of Hetrombopag Olamine. To investigate pharmacokinetics of Hetrombopag Olamine Under fasting conditions. To obtain pharmacodynamics information of Hetrombopag Olamine on platelet count elevation in healthy volunteers. To determine preliminary regimen for phase II study.

Official Title
-----------------
A Phase I, Randomized, Placebo-controlled, Ascending Single And Multiple Oral Dose Study To Investigate Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Hetrombopag Olamine (SHR8735 Olamine) In Healthy Subjects

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Drug: Hetrombopag Olamine Tablets
* Drug: placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subject must be adequately informed of the nature and risks of the study, able to understand the risks associated with the study, and are willing to provide written informed consent prior to screening. Must be a healthy male between the ages of 18 to 45 years, inclusive. Must have a BMI between 19 to 28 kg/m2, inclusive and a total body weight ≥50 kg. Platelet counts must be within the normal range. Subjects must be free of any clinically significant disease based on medical history and physical examination. Clinical laboratory tests (complete blood count [CBC], blood chemistries, and urinalysis) must be within the normal limits or clinically acceptable. Must be nonsmokers, defined as not having smoked tobacco or used chewing tobacco or nicotine. Subjects of reproductive potential with partners who are women of childbearing potential, will be instructed to, and must be willing to practice a highly effective method of birth control for the duration of the study and continuing 6 months after discontinuing treatment with the investigational product. Exclusion Criteria: History of hypersensitivity to hetrombopag olamine or its components. History or presence of significant cardiovascular deficient, pulmonary, hepatic, gallbladder or biliary tract, renal, hematological, gastrointestinal, endocrine, immunological, dermatological, neurological, or psychiatric disease, or any other condition known to interfere with the absorption, distribution, metabolism, or excretion of drugs. History of deep vein thrombosis, or any other thromboembolic event. History or presence of conditions that may place the subject at increased risk as determined by the investigator. History of thrombocytopenia or bleeding due to abnormal platelet number or function. History of platelet clumping that prevents reliable measurement of platelet counts.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: hetrombopag<br>hetrombopag either at 2.5,5,10,20,30 or 40mg, p.o. once daily | Drug: Hetrombopag Olamine Tablets<br> <br> |
| Placebo Comparator: placebo<br>Subjects will be randomized (5:1 eltrombopag : placebo) to receive either eltrombopag or placebo. | Drug: placebo<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in platelet count above baseline(%)on Day1,3,5,8,10,12,15,17,19,22,25,28 after dosing |  | up to 4 weeks | 
| Composite pharmacokinetic (PK) parameters of eltrombopag following a single dose of eltrombopag |  | For 5 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Adverse events |  | up to 4 weeks | 
| Change in vital signs |  | up to 4 weeks | 
| Change in clinical laboratory parameters |  | up to 4 weeks |